Details of the Drug Reposition

General Information of This Drug (ID: DMS8IFC)

Drug Name
Sorafenib   DMS8IFC
Synonyms
Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
7 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Medullary thyroid gland carcinoma DISHBL3K N.A. Approved [1]
Clear cell renal carcinoma DISBXRFJ N.A. Approved [1]
Carcinoma DISH9F1N 2A00-2F9Z Approved [1]
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Approved [1]
Renal cell carcinoma DISQZ2X8 2C90 Approved [2]
Thyroid cancer DIS3VLDH 2D10 Approved [1]
Adenocarcinoma DIS3IHTY 2D40 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Indications(s)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hepatocellular carcinoma DIS0J828 2C12.02 Phase 3 [2]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myelodysplastic syndrome DISYHNUI 2A37 Phase 2 [2]
------------------------------------------------------------------------------------
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Colorectal neoplasm DISR1UCN N.A. Discontinued in Phase 2 [3]
Thyroid gland undifferentiated (anaplastic) carcinoma DISYBB1W N.A. Discontinued in Phase 2 [4]
------------------------------------------------------------------------------------

References

1 Sorafenib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
3 Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia
4 ClinicalTrials.gov (NCT01652014) Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies